Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Receivables: 2022-2025

Historic Change in Receivables for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Sep 2025 value amounting to $8.4 million.

  • Arcutis Biotherapeutics' Change in Receivables fell 49.25% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.2 million, marking a year-over-year increase of 42.13%. This contributed to the annual value of $47.3 million for FY2024, which is 172.40% up from last year.
  • Arcutis Biotherapeutics' Change in Receivables amounted to $8.4 million in Q3 2025, which was down 60.38% from $21.3 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Change in Receivables high stood at $21.3 million for Q2 2025, and its period low was $2.2 million during Q3 2023.
  • For the 3-year period, Arcutis Biotherapeutics' Change in Receivables averaged around $9.7 million, with its median value being $8.4 million (2025).
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Change in Receivables soared by 651.54% in 2024, and later plummeted by 49.25% in 2025.
  • Arcutis Biotherapeutics' Change in Receivables (Quarterly) stood at $6.0 million in 2022, then rose by 6.02% to $6.4 million in 2023, then surged by 121.06% to $14.1 million in 2024, then slumped by 49.25% to $8.4 million in 2025.
  • Its Change in Receivables stands at $8.4 million for Q3 2025, versus $21.3 million for Q2 2025 and $12.3 million for Q1 2025.